Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDARA: ixazomib + daratumumab without dexamethasone in elderly relapsed/refractory multiple myeloma
2018-001646-34Phase 2Terminated
- Sponsor
- CHU Caen Normandie
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib and daratumumab in multiple myeloma (MM), sponsored by CHU Caen Normandie. Primary endpoint: Very Good Partial Response + Complete Response rate. Started May 2018; status: terminated.
02
Drugs
ixazomibdaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-001646-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001646-34.